|
|
|
| Expression and Immunological Analysis of Recombinant Tetravalent Envelope Domain III Protein of Dengue Virus |
| QIU Li-juan1,2, ZHAO Yu-jiao1,2, LI Duo1,2, HUANG Xin-wei1,2, WANG Xiao-dan1,2, XI Jue-min1,2, PAN Yue1,2, CHEN Jun-ying1,2, SUN Qiang-ming1,2 |
1. Institute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming 650118, China;
2. Yunnan Key Laboratory of Vaccine Research & Development on Severe Infectious Diseases, Kunming 650118, China |
|
|
|
Abstract Four serotypes of dengue virus (DENV1-4) circulate globally, causing more human illness than any other arthropod-borne virus. So far, licensed vaccine against dengue is not yet available. The greatest risk factor for severe dengue is a previous infection with a different DENV serotype. The theory for why sequential heterotypic infections increases risk of severe disease is "antibody- dependent enhancement" (ADE). Previous research determinants that the predominant immune response is against the E protein which is comprised of three structurally distinct domains (DI, DII, DIII). EDIII might exclusively generate potent neutralizing antibodies with little or no cross-reactivity, and therefore of reduced ability to promote ADE. This suggested that EDIII is more likely to be an attractive vaccine. Here, a tetravalent recombinant dengue domain III protein gene sequence were yeast expression optimized and synthesized, then expression plasmids were constructed and transducted into pichia pastoris to selected an high-efficiency expression strain. EDIII protein were obtained by inducing expression and purification followed by identification using SDS-PAGE, Western blot. The result showed that EDIII expression plasmid was successfully constructed and highly expressed in pichia pastoris. Mice immunized with tetravalent DENV DIII generated higher levels of serum titer. In conclusion, a tetravalent recombinant dengue domain III protein with high purity were obtained. It lays a good foundation for the development of dengue vaccine.
|
|
Received: 24 August 2015
Published: 11 January 2016
|
|
|
|
Cite this article:
QIU Li-juan, ZHAO Yu-jiao, LI Duo, HUANG Xin-wei, WANG Xiao-dan, XI Jue-min, PAN Yue, CHEN Jun-ying, SUN Qiang-ming. Expression and Immunological Analysis of Recombinant Tetravalent Envelope Domain III Protein of Dengue Virus. China Biotechnology, 2016, 36(1): 1-6.
URL:
https://manu60.magtech.com.cn/biotech/10.13523/j.cb.20160101 OR https://manu60.magtech.com.cn/biotech/Y2016/V36/I1/1
|
|
|
| [1] Rodriguez-Roche R 1, Gould E A.Understanding the dengue viruses and progress towards their control.BioMed Research International, 2013,13(4): 119-144.
[2] Gubler D J.The global emergence/resurgence of arboviral diseases as public health problems.Archives of Medical Research, 2002,33( 4): 330-342.
[3] Domingo C, Alves M J, de Ory F.International external quality control assessment for the serological diagnosis of dengue infections. BMC Infectious Diseases, 2015, (15):167.
[4] Guzman M G, Kouri G.Dengue: an update.Lancet Infect Dis, 2002, 2(1): 33-42.
[5] Bhatt S, Gething P W, Brady O J.The global distribution and burden of dengue.Nature, 2013, 496(7446): 504-507.
[6] McArthur M A, Sztein M B, Edelman R.Dengue vaccines: recent developments, ongoing challenges and current candidates.Expert Rev Vaccines, 2013, 12(8): 933-953.
[7] Lindenbach B D, Rice C M.Molecular biology of flaviviruses.Adv Virus Res, 2003, 59:23-61.
[8] Simmons C P, Farrar J J, Nguyen V V, et al.Dengue.N Engl J Med, 2012,366(15): 399-401.
[9] Halstead S B.Neutralization and antibody-dependent enhancement of dengue viruses.Adv Virus, 2003, 60(60):421-467.
[10] Dejnirattisai W, Jumnainsong A, Onsirisakul N, et al.Cross-reacting antibodies enhance dengue virus infection in humans.Science, 2010,328(5979): 745.
[11] Block K, Bodrigo W W, Quinn M, et al.A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice.Vaccine, 2010,28(51):8085-8094.
[12] Zhang F C, Zhao H, Li L H, et al. Severe dengue outbreak in Yunnan China, Int J Infect Dis, 2013, 2014(27):4-6.
[13] Shen J C, Luo L, Li L.The impacts of mosquito density and meteorological factors on dengue fever epidemics in Guangzhou China 2006-2014: a time-series analysis.Biomed Environ Sci, 2015; 28(5): 321-329.
[14] Chen B, Liu Q.Dengue fever in China.Lancet, 2015 385(9978): 1621-1622.
[15] Guzman M G, Eva H.Dengue.Lancet, 2015,385(9966): 453-465.
[16] Sariol C A, White L J.Utility, limitations, and future of non-human primates for dengue research and vaccine development.Front Immunol, 2014,5(5):452. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
